Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Suzanne Kyle

Newcastle AuthorsTitleYearFull text
Dr Celine Cano
Professor Jane Endicott
Dr Ian Hardcastle
Dr Claire Jennings
Suzanne Kyle
et al.		Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile2024
Dr Elaine Willmore
Suzanne Kyle
Dr Yan Zhao
Huw Thomas
Dr Kenneth Rankin
et al.		Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index2024
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.		Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Carlo Bawn
Dr Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.		PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
James Murray
Huw Thomas
Philip Berry
Suzanne Kyle
Dr Miranda Morton
et al.		Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules2014
Michael Batey
Dr Yan Zhao
Suzanne Kyle
Emeritus Professor Herbie Newell
Professor Nicola Curtin
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer2013
Dr Emma Haagensen
Suzanne Kyle
Dr Gary Beale
Dr Ross Maxwell
Emeritus Professor Herbie Newell
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition2012
Huw Thomas
Suzanne Kyle
Ivanda Pavlovska
Professor Nicola Curtin
The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice2011
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.		Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Huw Thomas
Suzanne Kyle
Rafal Zur
Dr Evan Mulligan
Professor Nicola Curtin
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance2010
Dr Asima Mukhopadhyay
Dr Ahmed Elattar
Dr Aiste McCormick
Sarah Wilkinson
Dr Yvette Drew
et al.		Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors2010
Huw Thomas
Suzanne Kyle
Tim Robson
Professor Nicola Curtin
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?2009
Suzanne Kyle
Huw Thomas
Dr Jane Mitchell
Professor Nicola Curtin
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer2008
Dr Yvette Drew
Suzanne Kyle
Professor Richard Edmondson
Professor Ruth Plummer
Professor Nicola Curtin
Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]2008
Huw Thomas
Dr Christopher Calabrese
Michael Batey
Suzanne Kyle
Emeritus Professor Herbie Newell
et al.		Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial2007
123